Top Qs
Timeline
Chat
Perspective
Andecaliximab
Monoclonal antibody From Wikipedia, the free encyclopedia
Remove ads
Andecaliximab (INN;[1] development code GS-5745) is an experimental humanized monoclonal antibody designed for the treatment of cancer and inflammatory diseases.
This drug was developed by Gilead Sciences, Inc.[2]
Phase II and phase III trials for gastric cancer or gastroesophageal junction adenocarcinoma completed in 2019.
Remove ads
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads